Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-09-30

Study Completion Date

2013-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This phase II trial is studying how well vorinostat works in treating patients with metastatic or unresectable melanoma. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Vorinostat in Treating Patients With Metastatic Melanoma of the Eye

NCT01587352

Metastatic Uveal Melanoma Stage IV Uveal Melanoma AJCC v7

ACTIVE_NOT_RECRUITING PHASE2

Vorinostat in Patients With Class 2 High Risk Uveal Melanoma

NCT03022565

Uveal Melanoma

WITHDRAWN EARLY_PHASE1

Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

NCT00119249

Stage III Melanoma Stage IV Melanoma

COMPLETED PHASE2

Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma

NCT00958074

Cutaneous T-cell Lymphoma Stage I Cutaneous T-cell Lymphoma Stage II Cutaneous T-cell Lymphoma Stage III +1 more

TERMINATED PHASE2

Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors

NCT00227513

Unspecified Adult Solid Tumor, Protocol Specific

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVE:

I. Determine the objective response rate in patients with metastatic or unresectable melanoma treated with vorinostat.

SECONDARY OBJECTIVES:

I. Determine time to progression in patients treated with this drug. II. Determine the utility of HP1 and/or macro H2A nuclear foci as biomarkers of response in patients treated with this drug.

III. Correlate the presence of 72R or 72P variant p53 polymorphisms with response and time to progression in patients treated with this drug.

IV. Determine gene expression profiles that may predict response to this drug and gene expression changes that occur after treatment with this drug in these patients.

OUTLINE: This is a multicenter study.

Patients receive oral vorinostat once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed for 4 weeks and then every 3 months thereafter.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ciliary Body and Choroid Melanoma, Medium/Large Size Extraocular Extension Melanoma Iris Melanoma Uveal Melanoma Recurrent Intraocular Melanoma Recurrent Melanoma Stage IV Melanoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm I

Patients will receive vorinostat by mouth once a day for 4 weeks. Treatment may repeat every 4 weeks for as long as benefit is shown. Patients will be evaluated for 4 weeks and every 3 months thereafter.

Group Type EXPERIMENTAL

vorinostat

Intervention Type DRUG

Patients will receive vorinostat by mouth once a day for 4 weeks. Treatment may repeat every 4 weeks for as long as benefit is shown. Patients will be evaluated for 4 weeks and every 3 months thereafter.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

vorinostat

Patients will receive vorinostat by mouth once a day for 4 weeks. Treatment may repeat every 4 weeks for as long as benefit is shown. Patients will be evaluated for 4 weeks and every 3 months thereafter.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

L-001079038 SAHA suberoylanilide hydroxamic acid Zolinza

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically/cytologically confirmed melanoma that is metastatic/unresectable
* Residual, recurrent, or metastatic disease by radiographic examination. Measurable disease (at least 1 lesion in at least 1 dimension (longest diameter) as \>20mm with conventional techniques or \>10mm with spiral CT scan, within 4 weeks prior to registration
* No prior therapy or 1 prior treatment (cytokine/chemotherapy/combination) for metastatic disease allowed. Patients should not take valproic acid, another histone deacetylase inhibitor, for at least 2 weeks prior to enrollment. At least 4 weeks from prior therapy to be eligible or 6 weeks if last regimen included BCNU or mitomycin C
* Age\>=18 years
* Life expectancy \>=3 months.
* ECOG\<2 (Karnofsky ≥60%)
* Leukocytes \>3,000/mcL
* Absolute neutrophil count \>1,500/mcL
* Platelets \>100,000/mcL
* Total bilirubin within institutional limits
* AST/ALT≤2.5Xinstitutional ULN
* Creatinine within institutional limits OR creatinine clearance \>60mL/min/1.73 m2 if creatinine levels above institutional limits
* Eligibility of patients taking medications with potential to affect activity/PK of Vorinostat will be determined by PI
* Must not use concomitant steroids except topical/inhaled use
* Vorinostat effects on developing human fetus are unknown. Women of childbearing potential (WOCBP) and sexually active males must agree to use accepted/effective contraception method prior to study entry and for duration of the study
* Ability to understand/willingness to sign written informed consent
* Must have paraffin block of tumor tissue available for future studies

Exclusion Criteria

* Chemotherapy/radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering study
* May not be receiving any other investigational agents
* Known brain metastases
* History of allergic reactions attributed to compounds of similar chemical/biologic composition to Vorinostat
* Uncontrolled intercurrent illness including but not limited to ongoing/active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
* Pregnant women excluded because Vorinostat is a HDAC inhibitor agent with potential for teratogenic or abortifacient effects
* HIV-positive patients receiving combination antiretroviral therapy are ineligible because of potential for PK interactions with Vorinostat

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No